Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) Products under Development by Stage of Development | 8 | 1 |
| P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) Products under Development by Therapy Area | 9 | 1 |
| P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) Products under Development by Indication | 10 | 1 |
| P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) Products under Development by Companies | 13 | 2 |
| P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) Therapeutics Assessment | 15 | 6 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) Companies Involved in Therapeutics Development | 21 | 3 |
| Momenta Pharmaceuticals, Inc. | 21 | 1 |
| Pfizer Inc. | 22 | 1 |
| Selexys Pharmaceuticals Corporation | 23 | 1 |
| P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) Drug Profiles | 24 | 14 |
| GM-0111 Drug Profile | 24 | 1 |
| necuparanib Drug Profile | 25 | 3 |
| pentosan polysulfate sodium Drug Profile | 28 | 1 |
| Polysaccharides to Inhibit P-Selectin and HLE for Age-Related Macular Degeneration Drug Profile | 29 | 1 |
| rivipansel sodium Drug Profile | 30 | 5 |
| SelG-1 Drug Profile | 35 | 2 |
| Small Molecules to Inhibit P-Selectin, L-Selectin and PMN Proteases for Oncology Drug Profile | 37 | 1 |
| P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) Dormant Projects | 38 | 2 |
| P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) Discontinued Products | 40 | 1 |
| P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) Featured News &Press Releases | 41 | 10 |
| Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO | 41 | 1 |
| May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting | 41 | 1 |
| Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study | 42 | 1 |
| Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study | 43 | 1 |
| Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel | 43 | 1 |
| Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology | 44 | 1 |
| Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel | 44 | 1 |
| Jun 23, 2015: Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease | 45 | 1 |
| Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer | 46 | 1 |
| May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting | 47 | 1 |
| Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015 | 47 | 1 |
| Mar 03, 2015: GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle Cell Disease | 48 | 1 |
| Dec 09, 2014: GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist Rivipansel at 56th ASH Annual Meeting | 49 | 1 |
| Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer | 49 | 1 |
| Nov 06, 2014: GlycoMimetics Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting | 50 | 1 |
| Appendix | 51 | 2 |
| Methodology | 51 | 1 |
| Coverage | 51 | 1 |
| Secondary Research | 51 | 1 |
| Primary Research | 51 | 1 |
| Expert Panel Validation | 51 | 1 |
| Contact Us | 51 | 1 |
| Disclaimer | 52 | 1 |